$KZIA One last big thing. If GBM Agile results are good don't forget about PRV (Primary Review Voucher) . Thats money added to the value of KZIA that they can use the voucher or sell to another biopharm like a carbon credit. If you take the average value of 200M of that voucher without value of Paxalisib 200M / Outstanding Shares of 8M = $25 share price WITHOUT Paxalisib.
  • 4
4 Likes